高齢者における tardive dyskinesia の発生率に関する見通し研究

B L Saltz¹, M G Woerner, J M Kane

¹Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY 11004.

JAMA

|November 6, 1991

まとめ

抗精神病薬を開始した高齢患者における遅発性運動障害の発生率は,43週間後に31%である. 精神病診断と早期のエクストラピラミダ症状は,この抗精神病薬の副作用のリスクを増やす.

科学分野:

ゲリアトリック精神科
臨床薬理学臨床薬理学とは

背景:

Tardive dyskinesia (TD) は,抗精神病薬の潜在的な副作用である.
高齢者は,年齢に関連する変化により,TDに敏感になる可能性があります.

研究の目的:

抗精神病薬治療を開始した高齢患者のTDの発生率を決定する.
この集団におけるTD発症に関連する危険因子を特定する.

主な方法:

55歳以上の神経麻酔薬未使用患者の縦断的なコホート研究.
患者は,基値で評価され,異常な非自発的な動きとエクストラピラミダル徴候を定期的に追跡した.
生存分析は,TDの発生率を計算するために使用されました.

主要な成果:

神経性麻痺薬による運動障害の累積的発生率は,43週間の治療で31%でした.
精神科の診断と早期にエクストラピラミダル症状が現れたことは,TDのリスクの高さに関連していた.
この研究では,160人の高齢患者 (平均年齢77歳,72%が女性) が参加しました.

結論:

抗精神病薬の治療を開始した高齢患者は,遅発性不運動症を発症する重大なリスクがあります.
精神科の診断と早期のエクストラピラミダ症状は,高齢者のTDの重要な危険因子です.
これらの発見は,この脆弱な集団における注意深いモニタリングの必要性を強調しています.

さらに関連する動画

05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

関連する概念動画

01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

関連する実験動画